Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Asset Writedowns and Impairment (2021 - 2024)

Trinity Biotech's Asset Writedowns and Impairment history spans 4 years, with the latest figure at -$962000.0 for Q4 2024.

  • On a quarterly basis, Asset Writedowns and Impairment fell 231.72% to -$962000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was -$2.6 million, a 81.68% increase, with the full-year FY2025 number at $2.2 million, up 254.62% from a year prior.
  • Asset Writedowns and Impairment hit -$962000.0 in Q4 2024 for Trinity Biotech, down from -$892000.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for TRIB hit a ceiling of $2.3 million in Q3 2022 and a floor of -$10.8 million in Q2 2023.
  • Historically, Asset Writedowns and Impairment has averaged -$2.2 million across 4 years, with a median of -$884000.0 in 2021.
  • Biggest five-year swings in Asset Writedowns and Impairment: plummeted 1983.82% in 2023 and later surged 95.88% in 2024.
  • Tracing TRIB's Asset Writedowns and Impairment over 4 years: stood at -$876000.0 in 2021, then crashed by 246.12% to -$3.0 million in 2022, then soared by 90.44% to -$290000.0 in 2023, then tumbled by 231.72% to -$962000.0 in 2024.
  • Business Quant data shows Asset Writedowns and Impairment for TRIB at -$962000.0 in Q4 2024, -$892000.0 in Q3 2024, and -$446000.0 in Q2 2024.